Clinical factors influencing normalization of prothrombin time after stopping warfarin: A retrospective cohort study

Thrombosis Journal

Volumn 6, Issue , 2008, Pages

  Schulman, Sam ^a   Elbazi, Rajae ^b   Zondag, Michelle ^a   O'Donnell, Martin ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; CELECOXIB; CITALOPRAM; CLARITHROMYCIN; DILTIAZEM; DISULFIRAM; FLUINDOSTATIN; FLUOROURACIL; FLUVOXAMINE; GEMCITABINE; INTERFERON; ITRACONAZOLE; LEVOFLOXACIN; OMEPRAZOLE; PACLITAXEL; PARACETAMOL; PHENYTOIN; PROPRANOLOL; QUINIDINE; ROPINIROLE; SERTRALINE; SIMVASTATIN; TETRACYCLINE; TOLTERODINE; UNINDEXED DRUG; VITAMIN K GROUP; WARFARIN;

AGED; ARTICLE; CLINICAL PRACTICE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG POTENTIATION; DRUG WITHDRAWAL; FEMALE; HEMOSTASIS; HUMAN; INTERNATIONAL NORMALIZED RATIO; INVASIVE PROCEDURE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PROTHROMBIN TIME; RETROSPECTIVE STUDY; RISK FACTOR; SURGICAL TECHNIQUE;

EID: 57049108139     PISSN: None     EISSN: 14779560     Source Type: Journal    
DOI: 10.1186/1477-9560-6-15     Document Type: Article

References (16)

1. Friberg J Gislason GH Gadsboll N Rasmussen JN Rasmussen S Abildstrom SZ Kober L Madsen M Torp-Pedersen C: Temporal trends in the prescription of vitamin K antagonists in patients with atrial fibrillation. J Intern Med 2006, 259:173-8. 10.1111/j.1365-2796.2005.01595.x 16420546
2. Caro JJ: An economic model of stroke in atrialTfibrillation: the cost of suboptimal oral anticoagulation. Am J Manag Care 2004, 10:S451-58. 15696909
3. Francis CW Pellegrini VD Jr Leibert KM Totterman S Azodo MV Harris CM Cox C Marder VJ: Comparison of two warfarin regimens in the prevention of venous thrombosis following total knee replacement. Thromb Haemost 1996. 75:706-11. 8725709
4. Schwarz UI Stein CM: Genetic determinants of dose and clinical outcomes in patients receiving oral anticoagulants. Clin Pharmacol Ther 2006. 80:7-12. 10.1016/j.clpt.2006.04.008 16815312
5. Wadelius M Pirmohamed M:CPharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J 2007. 7:99-111. 10.1038/ sj.tpj.6500417 16983400
6. Douketis JD Berger PB Dunn AS Jaffer AK Spyropoulos AC Becker RC Ansell J: The perioperative management of antithrombotic therapy: ACCP evidence-based clinical practice guidelines. Chest 2008. 133(Suppl):299-339S. 10.1378/chest.08-0675
7. Heimark LD Wienkers L Kunze K Gibaldi M Eddy AC Trager WF O'Reilly RA Goulart DA: The mechanism of the interaction between amiodarone and warfarin in humans. Clin Pharmacol Ther 1992. 51:398-407. 1563209
8. Holbrook AM Pereira JA Labiris R McDonald H Douketis JD Crowther M Wells PS: Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005, 165:1095-106. 10.1001/archinte.165.10.1095 15911722
9. Hylek EM Regan S Go AS Hughes RA Singer DE Skates SJ: Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin. Ann Intern Med 2001, 135:393-400. 11560452
10. Lubetsky A Shasha Y Olchovsky D Loebstein R Halkin H Ezra D: Impact of pre-treatment INR level on the effect of intravenous low dose vitamin K in patients with excessive anticoagulation. Thromb Haemost 2003, 90:71-6. 12876628
11. Whitlock RP Crowther MA Warkentin TE Blackall MH Farrokhyar F Teoh KH: Warfarin cessation before cardiopulmonary bypass: Lessons learned from a randomized controlled trial of oral vitamin K. Ann Thorac Surg 2007, 84:103-8. 10.1016/j.athoracsur.2007.03.014 17588394
12. White RH McKittrick T Hutchinson R Twitchell J: Temporary discontinuation of warfarin therapy: Changes in the international normalized ratio. Ann Intern Med 1995, 122:40-2. 7985894
13. Douketis JD Woods K Foster GA Crowther MA: Bridging anticoagulation with low-molecular-weight heparin after interruption of warfarin therapy is associated with a residual anticoagulant effect prior to surgery. Thromb Haemost 2005, 94:528-31. 16268467
14. Phillips EM Buchan DA Newman N Rajan A Zia S: Low-molecular-weight heparin may alter point-of-care assay for international normalized ratio. Pharmacotherapy 2005, 25:1341-7. 10.1592/phco.2005.25.10.1341 16185178
15. Fihn SD Callahan CM Martin DC McDonell MB Henikoff JG White RH: The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics. Ann Intern Med 1996, 124:970-9. 8624064
16. Garcia D Regan S Crowther M Hughes RA Hylek EM: Warfarin maintenance dosing patterns in clinical practice: Implications for safer anticoagulation in the elderly population. Chest 2005. 127:2049-56. 10.1378/chest.127.6.2049 15947319